Genetic deficiency underlying the indicated disease

The term 'Genetic deficiency underlying the indicated disease' is a non-specific descriptor used to characterize the underlying cause of a monogenic or polygenic disorder. It does not refer to a single molecular target such as a receptor or enzyme, but rather to the absence or malfunction of a gene product (NIH, 2023). In the pharmaceutical industry, this phrase is frequently used in the context of gene therapy or enzyme replacement therapy (ERT) where the goal is to provide a functional version of a missing protein or to correct a genetic mutation (Nature Reviews Drug Discovery, 2020). Because the 'indicated disease' is not specified, the exact biological function and molecular classification remain undefined for this entry. Common examples of specific targets that fall under this category include the CFTR protein in cystic fibrosis or the dystrophin protein in Duchenne muscular dystrophy. As a result, this entry is considered incorrect for structured target identification because it lacks the specificity required to define a unique therapeutic mechanism. Analysts must identify the specific gene or protein involved to assess the drug's interaction, efficacy, and safety profile. Therapeutic interventions for such deficiencies often involve complex modalities like viral vectors or CRISPR-based editing, which carry unique safety risks such as immunogenicity or off-target effects (Science, 2021).

Other names

Genetic defectInborn error of metabolismMonogenic disorderGene deficiency

Restoration of missing or defective protein function via gene therapy, mRNA therapy, or enzyme replacement.